



Summary of Financial Results in Fiscal 2017

		Ratio to revenue
Revenue	¥ 960.2 billion	-
Cost of sales	¥ 346.0 billion	36.0%
SG&A expenses	¥ 301.8 billion	31.4%
R&D expenses	¥ 236.0 billion	24.6%
Operating profit	¥ 76.3 billion	7.9%
Profit attributable to owners of the Company	¥ 60.3 billion	6.3%
ROE	5.2%	
Liabilities	¥ 764.7 billion	
Net assets	¥ 1,133.0 billion	
Total assets	¥ 1,897.8 billion	
Equity ratio	59.7%	



Employees and Bases (As of March 31, 2018)



Key Products

Innovative Pharmaceuticals Business		
 Global Anticoagulant LIXIANA/SAVAYSA Generic name <i>Edoxaban</i> Revenue in fiscal 2017: ¥77.1 billion	 Global Antihypertensive agent Olmotec/Benicar Generic name <i>Olmesartan</i> Revenue in fiscal 2017: ¥149.7 billion	 Japan Ulcer treatment NEXIUM Generic name <i>Esomeprazole</i> Revenue in fiscal 2017: ¥86.5 billion
 Generic Business Antihypertensive agent Olmesartan (AG)	 Vaccine Business Seasonal influenza vaccine Influenza HA Vaccine	 OTC Related Business Antipyretic analgesics/ Topical anti-inflammatory analgesics Loxonin S

R&D Pipeline Highlights (As of July 2018)

	Phase 1-2 studies	Studies conducted for applications
Oncology	ADC Franchise ▶ Number of projects: 2 ▶ Target indications: 5	▶ Number of projects: 1 ▶ Target indications: 2
	AML Franchise ▶ Number of projects: 4 ▶ Target indications: 7	▶ Number of projects: 1 ▶ Target indications: 1
	Breakthrough Science ▶ Number of projects: 2 ▶ Target indications: 2	▶ Number of projects: 2 ▶ Target indications: 2
Specialty Medicine	▶ Number of projects: 4 ▶ Target indications: 4	▶ Number of projects: 5 ▶ Target indications: 7
Vaccines	▶ Number of projects: 1 ▶ Target indications: 1	▶ Number of projects: 3 ▶ Target indications: 3

Major R&D Pipeline(In-House Development Projects)

(As of July 2018)

*1 Phase 1: Conduct trials on a small group of healthy volunteers to assess safety and pharmacokinetics of drugs (patient volunteers may be included depending on the trial)
*2 Phase 2: Conduct trials on a small group of patient volunteers to assess safety, efficacy, dosage and administration regimen
*3 Phase 3: Conduct trials on a large number of patient volunteers to assess safety and efficacy of a new drug in comparison with existing drugs
★: Projects in the field of oncology which are planned for application based on the results of Phase 2 trials

Generic Name/Project Code Number	Class	Target indication	Region	Stage					Partner	Remarks			
				Pre-clinical	P1*1	P2*2	P3*3	Submitted					
Oncology													
ADC Franchise	DS-8201	Anti-HER2 antibody drug conjugate	Metastatic breast cancer (HER2 positive post T-DM1)	JP/US/EU/Asia	██████████	██████████	██████████	██████████	██████████	★	Granted Fast Track Designation by the FDA Granted Breakthrough Therapy Designation by the FDA		
			Metastatic breast cancer (HER2 positive vs. T-DM1)	JP/US/EU/Asia	██████████	██████████	██████████	██████████	██████████				
			Metastatic breast cancer (HER2 low expression)	JP/US/EU	██████████	██████████	██████████	██████████	██████████				
			Metastatic gastric cancer (HER2 expressing post trastuzumab)	JP/Asia	██████████	██████████	██████████	██████████	██████████	★		Granted SAKIGAKE Designation by the Ministry of Health, Labour and Welfare	
			Colorectal cancer	JP/US/EU	██████████	██████████	██████████	██████████	██████████				
			Non-small cell lung cancer	JP/US/EU	██████████	██████████	██████████	██████████	██████████				
			Metastatic breast cancer, urothelial (bladder) cancer	US/EU	██████████	██████████	██████████	██████████	██████████			BMS	Combination with <i>nivolumab</i>
			U3-1402	Anti-HER3 antibody drug conjugate	Metastatic breast cancer	JP/US	██████████	██████████	██████████	██████████		██████████	
			DS-1062	Anti-TROP2 antibody drug conjugate	Non-small cell lung cancer	US	██████████	██████████	██████████	██████████		██████████	
			DS-7300	Anti-B7-H3 antibody drug conjugates	Solid tumors	JP/US	██████████	██████████	██████████	██████████		██████████	
DS-6157	Antibody drug conjugates	GIST (Gastrointestinal stromal tumor)	-	██████████	██████████	██████████	██████████	██████████					
DS-6000	Antibody drug conjugates	Renal cancer, ovarian cancer	-	██████████	██████████	██████████	██████████	██████████					
-	Anti-TA-MUC1 antibody drug conjugates	Solid tumors	-	██████████	██████████	██████████	██████████	██████████		GlycoTope			
AML Franchise	Quizartinib/AC220	FLT3 inhibitor	Acute myeloid leukemia (relapsed / refractory)	US/EU/Asia	██████████	██████████	██████████	██████████	██████████		Granted Fast Track Designation by the FDA Granted Orphan Drug Designation by the FDA and the EMA		
			Acute myeloid leukemia (first-line)	JP/US/EU/Asia	██████████	██████████	██████████	██████████	██████████				
			Acute myeloid leukemia (relapsed / refractory)	JP	██████████	██████████	██████████	██████████	██████████				
	Milademetan/DS-3032	MDM2 inhibitor	Solid tumors	JP/US	██████████	██████████	██████████	██████████	██████████				
			Acute myeloid leukemia	US	██████████	██████████	██████████	██████████	██████████		Added a combination cohort with <i>azacitidine</i>		
			Acute myeloid leukemia	US	██████████	██████████	██████████	██████████	██████████		Combination with <i>quizartinib</i>		
	DS-3201	EZH1/2 inhibitor	Adult T-cell leukemia/lymphoma, peripheral T-cell lymphoma	JP	██████████	██████████	██████████	██████████	██████████				
	PLX51107	BRD4 inhibitor	Acute myeloid leukemia, myelodysplastic syndrome, solid tumor	US	██████████	██████████	██████████	██████████	██████████				
DS-1001	IDH1 mutant inhibitor	Glioma	JP	██████████	██████████	██████████	██████████	██████████					
PLX2853	BRD4 inhibitor	Acute myeloid leukemia, solid tumors	US	██████████	██████████	██████████	██████████	██████████					
Pexidartinib	CSF-1R/KIT/FLT3 inhibitor	Tenosynovial giant cell tumor	US/EU	██████████	██████████	██████████	██████████	██████████		Granted Breakthrough Therapy Designation by the FDA			
Breakthrough Science	DS-1647(G47A)	Oncolytic HSV-1	Glioblastoma	JP	██████████	██████████	██████████	██████████	██████████	★	Granted SAKIGAKE Orphan Drug Designation by the Ministry of Health, Labour and Welfare		
	DS-1205	AXL inhibitor	Non-small cell lung cancer	JP/US	██████████	██████████	██████████	██████████	██████████		Combination with <i>osimertinib</i> (US) or <i>gefitinib</i> (JP)		
	Axicabtagene ciloleucel	Anti-CD19 CAR-T cells	Large B Cell Lymphoma	JP	██████████	██████████	██████████	██████████	██████████		Kite/Gilead		

Specialty medicine											
The field of Cardiovascular-Metabolics	Edoxaban/DU-176b	Factor Xa inhibitor	Atrial fibrillation (AF)	ASCA	██████████	██████████	██████████	██████████	██████████		BR: received approval in Mar 2018 CN: submitted in Aug 2015
			Venous thromboembolism	ASCA	██████████	██████████	██████████	██████████	██████████		BR: received approval in Mar 2018 CN: submitted in Aug 2015
			Very elderly patients with non-valvular AF	JP	██████████	██████████	██████████	██████████	██████████		Additional dosage and formulation for very elderly (80 years and older) AF patients
	Prasugrel/CS-747	Anti-platelet agent	Ischemic stroke	JP	██████████	██████████	██████████	██████████	██████████		Ube Industries Additional indication, P3 studies completed
	Esaxerenone/CS-3150	MR antagonist	Hypertension Diabetic nephropathy	JP JP	██████████ ██████████	██████████ ██████████	██████████ ██████████	██████████ ██████████	██████████ ██████████		Exelixis, Inc. Submitted in Feb 2018
	DS-1040	TAFIa inhibitor	Acute ischemic stroke, acute pulmonary embolism	JP/US/EU	██████████	██████████	██████████	██████████	██████████		
DS-2330	Hyperphosphatemia treatment	Hyperphosphatemia in chronic kidney disease	-	██████████	██████████	██████████	██████████	██████████			
The field of Internal Medicine	Mirogabalin/DS-5565	α2δ ligand	Diabetic peripheral neuropathic pain Postherpetic neuralgia	JP/Asia	██████████	██████████	██████████	██████████	██████████		JP: submitted in Feb 2018
	Laninamivir/CS-8958	Neuraminidase inhibitor	Influenza	JP	██████████	██████████	██████████	██████████	██████████		Additional dosage form, nebulizer formulation Submitted in Jul 2018
	DS-5141	ENA oligonucleotide	Duchenne muscular dystrophy	JP	██████████	██████████	██████████	██████████	██████████		Granted SAKIGAKE Designation by the Ministry of Health, Labour and Welfare
	DS-1211	TNAP inhibitor	Prevention of ectopic calcification diseases	US	██████████	██████████	██████████	██████████	██████████		Research collaboration with Sanford Burnham Prebys Medical Discovery Institute

Vaccines											
VN-0107/MEDI3250	Nasal cavity spray live attenuated influenza vaccine	Prevention of seasonal influenza	JP	██████████	██████████	██████████	██████████	██████████	██████████		AstraZeneca/MedImmune Submitted by Daiichi Sankyo in Jun 2016
VN-100	Intradermal seasonal influenza vaccine	Prevention of seasonal influenza	JP	██████████	██████████	██████████	██████████	██████████	██████████		Terumo Corporation
VN-0105	DPT-IPV/Hib vaccine	Prevention of pertussis, diphtheria, tetanus, poliomyelitis and Hib	JP	██████████	██████████	██████████	██████████	██████████	██████████		Sanofi Pasteur Co-develop with Sanofi K.K. and KDSV
VN-0102/JVC-001	Measles-Mumps-Rubella vaccine	Prevention of Measles, Mumps and Rubella	JP	██████████	██████████	██████████	██████████	██████████	██████████		Japan vaccine company is preparing for the P3 study